Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17703906 | 0.91 | TRPV3 (0.48) | TRPV3SMN1; SMN2POLBALDH1A1ALOX12 | |
| SCHEMBL16729555 | 0.84 | ALDH1A1 (0.45) | TRPV3ALDH1A1LMNAADRA1AKMT2A | |
| SCHEMBL18252826 | 0.79 | ALDH1A1 (0.41) | ALDH1A1LMNAADRA1AKMT2AIDH1 | |
| SCHEMBL12765145 | 0.74 | NOS1 (0.43) | IDH1TACR1 | |
| SCHEMBL16727050 | 0.73 | ALDH1A1 (0.50) | TRPV3ALDH1A1LMNAADRA1AKMT2A | |
| SCHEMBL13461889 | 0.73 | TACR1 (0.50) | TACR1 | |
| SCHEMBL19443084 | 0.73 | RAPGEF4 (0.41) | IDH1TACR1 | |
| SCHEMBL799344 | 0.72 | RXRA (0.45) | IDH1 | |
| SCHEMBL8060845 | 0.72 | ALDH1A1 (0.55) | SMN1; SMN2POLBALDH1A1ALOX12LMNA | |
| SCHEMBL799008 | 0.70 | IDO1 (0.41) | LMNAADRA1AIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | TRPV3 3349/4885SMN1; SMN2 2858/4885POLB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.